QuidelOrtho to Report Second Quarter 2025 Financial Results
SAN DIEGO, July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2025 ended June 29, 2025, after the market close on Tuesday, August 5, 2025.
Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.com. Presentation materials will also be posted to the "Events & Presentations" section of the "Investor Relations" page of the Company's website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 689337.
A replay of the conference call will be available shortly after the event on the "Investor Relations" page of the Company's website under the "Events & Presentations" section.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic.
Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@quidelortho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@quidelortho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-to-report-second-quarter-2025-financial-results-302511072.html
SOURCE QuidelOrtho Corporation
Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Nachrichten zu Quidel Corp.
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Quidel Corp.
Datum | Rating | Analyst | |
---|---|---|---|
22.01.2018 | Quidel Overweight | Barclays Capital | |
18.07.2017 | Quidel Buy | Canaccord Adams | |
25.04.2017 | Quidel Hold | Canaccord Adams | |
08.01.2016 | Quidel Buy | Canaccord Adams | |
02.09.2015 | Quidel Overweight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
22.01.2018 | Quidel Overweight | Barclays Capital | |
18.07.2017 | Quidel Buy | Canaccord Adams | |
08.01.2016 | Quidel Buy | Canaccord Adams | |
02.09.2015 | Quidel Overweight | Barclays Capital | |
04.01.2011 | Quidel outperform | Wedbush Morgan Securities Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
25.04.2017 | Quidel Hold | Canaccord Adams | |
03.03.2011 | Quidel neutral | Wedbush Morgan Securities Inc. | |
30.09.2009 | Quidel market perform | William Blair |
Datum | Rating | Analyst | |
---|---|---|---|
29.08.2006 | Update Quidel Corp.: Strong Sell | Matrix Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Quidel Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen